Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2011

View Archived Issues

Phase II trial evaluates dutasteride in spinal and bulbar muscular atrophy / News in Context

Russian scientists claim new melanocortin MC2 receptor ligands

DA-1229 may be beneficial in diabetes types 1 and 2

Talactoferrin increases survival of patients with septic shock and systolic dysfunction

Ironwood Pharma and Protagonist Therapeutics join to develop new peptide therapeutics

MAb 1C11 impairs growth of S. aureus and may be candidate drug for MRSA-associated osteomyelitis

Therapure Biopharma describes hemoglobin-drug conjugates for targeted delivery to the liver

Zalicus provides update on product candidates and collaborations

Cadence Pharma launches Ofirmev in U.S. for pain and fever

Johns Hopkins Brain Science Institute and Ortho-McNeil-Janssen enter collaboration

New inhibitors claimed of Egl nine homolog 1, 2 and 3

Dainippon Sumitomo claims new dopamine D2 receptor ligands

New inhibitors of JAK1, JAK2 and JAK3 developed at Genentech

Targacept reports phase II data on TC-5619 in schizophrenia

Ono Pharmaceutical divulges new chymase inhibitors

DWTI identifies new substituted isoquinoline derivatives

UCB provides update on development milestones

Ono Pharma claims new agents for urinary incontinence

Alexza completes end-of-review meeting with FDA regarding AZ-004

GSK-2402968 enters phase III trial in Duchenne's muscular dystrophy

PROLOR and Yeda sign agreement for reversible PEGylation technology

Harbor BioSciences licenses three compounds to CIPI in China

Zanamivir enters phase III trial in hospitalized patients with influenza

FDA issues complete response letter to MannKind regarding Afrezza NDA

Lundbeck begins phase III program for zicronapine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...